Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1700)	2/18/2003 9:46:05 AM
From: WhatsUpWithThat	Read Replies (1) \| Respond to of 2243

FWIW, ARDN saw a real bump in volume last week and now the price is responding, though on low vol. I don't know if this is one you follow, though I note tuck's name on the ARDN thread. Regards WUWT

To: scaram(o)uche who wrote (1700)	2/18/2003 10:21:24 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2243

LJPC...... They're talking subset, when this is ALREADY a trial that resulted from subset analysis. Ticks me off, that the sector is still weighed down with companies that are playing out old stories (there are comments somewhere in one of the T/FIF threads re. the departure of Stephen Coutts, etc.). This makes me 100% on calls for due diligence jobs while I was consulting for underwriters, if you call a "go" for LeukoSite to be a good call. Decent retainers, I eventually couldn't get enough daily work. I said "no go" too often. The fact is that underwriters, etc. wanted rubber stamp consultants.